En nous appuyant sur les recherches pionnières des fondateurs de notre Institut, nous continuons à mener des recherches de pointe sur les probiotiques, le microbiote intestinal et la santé intestinale. Nos travaux se concentrent sur le développement et l’optimisation de compléments alimentaires (probiotiques traditionnels, probiotiques de nouvelle génération, synbiotiques et postbiotiques) conçus pour maintenir l’équilibre du microbiome et remédier à la dysbiose. Ces bienfaits sont mis à profit dans la prise en charge de diverses affections, notamment la diarrhée infectieuse et associée aux antibiotiques, et dans le cadre du traitement standard visant à éradiquer Helicobacter pylori.

Grâce à la recherche préclinique et clinique, nous validons non seulement les bienfaits de nos probiotiques pour la santé, mais nous découvrons également leurs mécanismes d’action sous-jacents. Nous soutenons les méthodologies innovantes de nos collaborateurs qui permettent une analyse précise de la dynamique microbienne dans l’intestin grêle. Parallèlement, des études cliniques démontrent les bienfaits considérables des probiotiques sur diverses populations et dans diverses conditions, des bébés prématurés aux personnes souffrant du syndrome du côlon irritable (SCI). En plus des travaux menés en interne, nos souches sont utilisées dans des études menées par des experts mondiaux du microbiome et contribuent à élargir les connaissances et les preuves scientifiques sur les bienfaits des probiotiques.

Publications choisies

  1. Auclair-Ouellet, N., Tremblay, A., Kassem, O., Caballero-Calero, S. E., Bronner, S., & Binda, S. (2025). Probiotics as Adjuvants to Standard Helicobacter pylori Treatment: Evidence for the Use of Lacidofil®, an Established Blend of Thoroughly Characterized Strains. Microorganisms, 13(10), 2223. https://doi.org/10.3390/microorganisms13102223 
  2. Connan, C., Fromentin, S., Benallaoua, M., Alvarez, A.-S., Pons, N., Quinquis, B., Morabito, C., Nazare, J.-A., Borezée-Durant, E., Le French Gut Consortium, Haimet, F., Dusko Ehrlich, S., Valeille, K., Cavezza, A., Blottière, H., Veiga, P., Almeida, M., Doré, J., & Benamouzig, R. (2025). Associations among diet, health, lifestyle, and gut microbiota composition in the general French population: Protocol for Le French Gut – Le microbiote français study. JMIR Research Protocols, 14, e64894. https://doi.org/10.2196/64894  
  3. Deschamps, C., Humbert, D., Brun, M., Denis, S., Durif, C., Apper, E., & Blanquet-Diot, S. (2025). Lactobacillus helveticus-derived postbiotic and live Saccharomyces boulardii restore gut microbiota after antibiotic disturbance in an in vitro canine gut model. Beneficial Microbes, 1-21. https://doi.org/10.1163/18762891-bja00088
  4. Dong, X., Han, S., Zha, H., & Li, L. (2025). Lactobacillus helveticus R0052 attenuates DSS-induced colitis via modulation of gut microbiota, intestinal metabolites and immunological profiles in a mouse model. Microbial Pathogenesis, 208, 108002. https://doi.org/10.1016/j.micpath.2025.108002
  5. Duysburgh, C., Nicolas, C., Van Den Broeck, M., Lloret, F., Monginoux, P., Rème, C., & Marzorati, M. (2025). A specific blend of prebiotics and postbiotics improved the gut microbiome of dogs with soft stools in the in vitro Simulator of the Canine Intestinal Microbial Ecosystem. Journal of animal science, 103. https://doi.org/10.1093/jas/skaf056
  6. Lu, F., MacPherson, C. W., Iskandar, M. M., & Kubow, S. (2025). Probiotic secretomes attenuate inflammation and disrupted antioxidant status induced by polychlorinated biphenyls in human intestinal T84 epithelial cells. Free Radical Biology and Medicine, 239, 367-385. https://doi.org/10.1016/j.freeradbiomed.2025.07.008  
  7. Marbou Takougoum, J. W., Whiteside, S. A., Carroll, D. G., Mohiuddin, M. M., Bronner, S., Binda, S., & Creuzenet, C. (2025). Assays for anti-Helicobacter pylori effects of lactic acid bacteria secretions. In I. Brockhausen (Ed.), Dynamics of Bacteria-Mucus Interactions (pp. 63-79). Springer Nature. https://pubmed.ncbi.nlm.nih.gov/40498307/
  8. Creuzenet, C., Carroll, D., Takougoum, J. M., Mohiuddin, M., Auger, J., McAlister, J., Geddes-Mcalister, J., Bronner, S., & Binda, S. (2024). A183 Secretions of Lactic Acid Bacteria as Anti-Helicobacter pylori agents. Journal of the Canadian Association of Gastroenterology, 7(Supplement_1), 144-144. https://doi.org/10.1093/jcag/gwad061.183  
  9. Jeffrey, M. P., Saleem, L., Macpherson, C. W., Tompkins, T. A., Clarke, S. T., & Green-Johnson, J. M. (2024). A Lacticaseibacillus rhamnosus secretome induces immunoregulatory transcriptional, functional and immunometabolic signatures in human THP-1 monocytes. Scientific Reports, 14(1), 8379. https://doi.org/10.1038/s41598-024-56420-8  
  10. Wang, G., Menon, S., Wilsack, L., Rehak, R., Lou, L., Turbide, C., Auger, J., Tremblay, A., Mathieu, O., & Binda, S. (2024). Spatially and temporally precise microbiome profiling in the small intestine using the SIMBA capsule with X-ray tracking. Frontiers in Microbiomes, 3, 1321624. https://doi.org/10.3389/frmbi.2024.1321624  
  11. Ait Chait, Y., Mottawea, W., Tompkins, T. A., & Hammami, R. (2023). Evidence of the dysbiotic effect of psychotropics on gut microbiota and capacity of probiotics to alleviate related dysbiosis in a model of the human colon. International Journal of Molecular Sciences, 24(8), 7326. https://doi.org/10.3390/ijms24087326
  12. Kiattiweerasak, A., Aumpan, N., Pornthisarn, B., Chonprasertsuk, S., Siramolpiwat, S., Bhanthumkomol, P., Nunanan, P., Issariyakulkarn, N., Mahachai, V., & Vilaichone, R. (2023). Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as adjuvant for Helicobacter pylori eradication: A double-blind, randomized, placebo-controlled study. Frontiers in Gastroenterology, 2, 1245993. https://doi.org/10.3389/fgstr.2023.1245993 
  13. Legan, T. B., Lavoie, B., Norberg, E., Ley, I. C., Tack, S., Tompkins, T. A., Wargo, M. J., & Mawe, G. M. (2023). Tryptophan‐synthesizing bacteria enhance colonic motility. Neurogastroenterology & Motility, 35(10), e14629. https://doi.org/10.1111/nmo.14629  
  14. Rawling, M., Schiavone, M., Mugnier, A., Leclercq, E., Merrifield, D., Foey, A., & Apper, E. (2023). Modulation of zebrafish (Danio rerio) intestinal mucosal barrier function fed different postbiotics and a probiotic from Lactobacilli. Microorganisms, 11(12), 2900. https://doi.org/10.3390/microorganisms11122900 
  15. Taibi, A., Tokar, T., Tremblay, J., Gargari, G., Streutker, C. J., Li, B., Pierro, A., Guglielmetti, S., Tompkins, T. A., & Jurisica, I. (2023). Intestinal microRNAs and bacterial taxa in juvenile mice are associated, modifiable by allochthonous lactobacilli, and affect postnatal maturation. Msystems, 8(4), e00431-00423. https://doi.org/10.1128/msystems.00431-23  
  16. Tremblay, A., Xu, X., Colee, J., Tompkins, T. A., & Binda, S. (2023). Effectiveness of Medilac-S as an adjuvant to conventional Irritable Bowel Syndrome treatments: A systematic review with meta-analysis. Gastroenterology Insights, 14(4), 491-514. https://doi.org/10.3390/gastroent14040036  
  17. Tremblay, A., Bronner, S., & Binda, S. (2023). Review and Perspectives on Bifidobacterium lactis for Infants’ and Children’s Health. Microorganisms, 11(10), 2501. https://doi.org/10.3390/microorganisms11102501  
  18. Tremblay, A., Auger, J., Alyousif, Z., Calero, S. E. C., Mathieu, O., Rivero-Mendoza, D., Elmaoui, A., Dahl, W. J., & Tompkins, T. A. (2023). Total transit time and probiotic persistence in healthy adults: A pilot study. Journal of Neurogastroenterology and Motility, 29(2), 218-228. https://doi.org/10.5056/jnm22031  
  19. Brown, B. E., Huisman, E., Miller, M. R., Ulrich, C., Reid, G., & Da Silva, O. (2022). Enteral supplementation with probiotics in preterm infants: A retrospective cohort study and 6-year follow-up. Frontiers in Nutrition, 9, 1063121. https://doi.org/10.3389/fnut.2022.1063121
  20. Gagné, M.-A., Barbeau, C., Frégeau, G., Gilbert, K., Mathieu, O., Auger, J., Tompkins, T. A., Charbonney, E., Godbout, R., & Rousseau, G. (2022). Dysbiotic microbiota contributes to the extent of acute myocardial infarction in rats. Scientific Reports, 12(1), 16517. https://doi.org/10.1038/s41598-022-20826-z  
  21. Gupta, H., Kim, S. H., Kim, S. K., Han, S. H., Kwon, H. C., & Suk, K. T. (2022). Beneficial shifts in gut microbiota by Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 in alcoholic hepatitis. Microorganisms, 10(7), 1474. https://doi.org/10.3390/microorganisms10071474  
  22. Jeffrey, M. P., Macpherson, C. W., Tompkins, T. A., & Green-Johnson, J. M. (2022). Lacticaseibacillus rhamnosus R0011 secretome attenuates Salmonella enterica serovar Typhimurium secretome-induced intestinal epithelial cell monolayer damage and pro-inflammatory mediator production in intestinal epithelial cell and antigen-presenting cell co-cultures. Frontiers in Microbiology, 13, 980989. https://doi.org/10.3389/fmicb.2022.980989  
  23. Nogacka, A. M., Arboleya, S., Nikpoor, N., Auger, J., Salazar, N., Cuesta, I., Alvarez-Buylla, J. R., Mantecón, L., Solís, G., Gueimonde, M., Tompkins, T. A., & De Los Reyes-Gavilán, C. G. (2022). In vitro probiotic modulation of the intestinal microbiota and 2′fucosyllactose consumption in fecal cultures from infants at two months of age. Microorganisms, 10(2), 318. https://doi.org/10.3390/microorganisms10020318  
  24. Pi, X., Teng, W., Fei, D., Zhao, G., & Liu, W. (2022). Effects of live combined Bacillus subtilis and Enterococcus faecium on gut microbiota composition in C57BL/6 mice and in humans. Frontiers in Cellular and Infection Microbiology, 12, 821662. https://doi.org/10.3389/fcimb.2022.821662
  25. Samara, J., Moossavi, S., Alshaikh, B., Ortega, V. A., Pettersen, V. K., Ferdous, T., Hoops, S. L., Soraisham, A., Vayalumkal, J., Dersch-Mills, D., Gerber, J. S., Mukhopadhyay, S., Puopolo, K., Tompkins, T. A., Knights, D., Walter, J., Amin, H., & Arrieta, M.-C. (2022). Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants. Cell Host & Microbe, 30(5), 696-711.e695. https://doi.org/10.1016/j.chom.2022.04.005  
  26. Ait Chait, Y., Mottawea, W., Tompkins, T. A., & Hammami, R. (2021). Nutritional and therapeutic approaches for protecting human gut microbiota from psychotropic treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 108, 110182. https://doi.org/https://doi.org/10.1016/j.pnpbp.2020.110182  
  27. Dahl, W. J., Auger, J., Alyousif, Z., Miller, J. L., & Tompkins, T. A. (2021). Adults with Prader–Willi syndrome exhibit a unique microbiota profile. BMC Research Notes, 14(1). https://doi.org/10.1186/s13104-021-05470-6  
  28. Nogacka, A. M., Arboleya, S., Nikpoor, N., Auger, J., Salazar, N., Cuesta, I., Mantecón, L., Solís, G., Gueimonde, M., Tompkins, T. A., & De Los Reyes-Gavilán, C. G. (2021). Influence of 2′-fucosyllactose on the microbiota composition and metabolic activity of fecal cultures from breastfed and formula-fed infants at two months of age. Microorganisms, 9(7), 1478. https://doi.org/10.3390/microorganisms9071478   
  29. Schreiber, C., Tamir, S., Golan, R., Weinstein, A., & Weinstein, Y. (2021). The effect of probiotic supplementation on performance, inflammatory markers and gastro‐intestinal symptoms in elite road cyclists. Journal of the International Society of Sports Nutrition, 18(1). https://doi.org/10.1186/s12970-021-00432-6  
  30. Tremblay, A., Fatani, A., Ford, A. L., Piano, A., Nagulesapillai, V., Auger, J., Macpherson, C. W., Christman, M. C., Tompkins, T. A., & Dahl, W. J. (2021). Safety and effect of a low- and high-dose multi-strain probiotic supplement on microbiota in a general adult population: A randomized, double-blind, placebo-controlled study. Journal of Dietary Supplements, 18(3), 227-247. https://doi.org/10.1080/19390211.2020.1749751 
  31. Whiteside, S. A., Mohiuddin, M. M., Shlimon, S., Chahal, J., MacPherson, C. W., Jass, J., Tompkins, T. A., & Creuzenet, C. (2021). In vitro framework to assess the anti-Helicobacter pylori potential of lactic acid bacteria secretions as alternatives to antibiotics. International Journal of Molecular Sciences, 22(11), 5650. https://doi.org/10.3390/ijms22115650  
  32. Ait Chait, Y., Mottawea, W., Tompkins, T. A., & Hammami, R. (2020). Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Scientific Reports, 10(1), 17878. https://doi.org/10.1038/s41598-020-74934-9  
  33. Lewis, E. D., Antony, J. M., Crowley, D. C., Piano, A., Bhardwaj, R., Tompkins, T. A., & Evans, M. (2020). Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of Irritable Bowel Syndrome (IBS): A randomized, placebo-controlled study. Nutrients, 12(4), 1159. https://doi.org/10.3390/nu12041159
  34. Sato, R., Malai, S., & Razmjouy, B. (2020). Necrotizing enterocolitis reduction using an exclusive human‐milk diet and probiotic supplementation in infants with 1000–1499 gram birth weight. Nutrition in Clinical Practice, 35(2), 331-334. https://doi.org/10.1002/ncp.10394  
  35. MacPherson, C. W., Mathieu, O., Tremblay, J., Champagne, J., Nantel, A., Girard, S. A., & Tompkins, T. A. (2018). Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Scientific Reports, 8(1), 11192. https://doi.org/10.1038/s41598-018-29229-5  
  36. Sohail, G., Xu, X., Christman, M. C., & Tompkins, T. A. (2018). Probiotic Medilac-S® for the induction of clinical remission in a Chinese population with ulcerative colitis: A systematic review and meta-analysis. World Journal of Clinical Cases, 6(15), 961-984. https://doi.org/10.12998/wjcc.v6.i15.961   
  37. Martinelli, M., Ummarino, D., Giugliano, F. P., Sciorio, E., Tortora, C., Bruzzese, D., De Giovanni, D., Rutigliano, I., Valenti, S., Romano, C., Campanozzi, A., Miele, E., & Staiano, A. (2017). Efficacy of a standardized extract of Matricariae chamomilla L., Melissa officinalis L. and tyndallized Lactobacillus acidophilus (HA122) in infantile colic: An open randomized controlled trial. Neurogastroenterology & Motility, 29(12), e13145. https://doi.org/https://doi.org/10.1111/nmo.13145  
  38. Evans, M., Salewski, R. P., Christman, M. C., Girard, S. A., & Tompkins, T. A. (2016). Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. British Journal of Nutrition, 116(1), 94-103. https://doi.org/10.1017/s0007114516001665
  39. Dilli, D., Aydin, B., Fettah, N. D., Özyazıcı, E., Beken, S., Zenciroğlu, A., Okumuş, N., Özyurt, B. M., İpek, M. Ş., & Akdağ, A. (2015). The ProPre-Save study: Effects of probiotics and prebiotics alone or combined on necrotizing enterocolitis in very low birth weight infants. The Journal of Pediatrics,166(3), 545-551. e541. https://doi.org/10.1016/j.jpeds.2014.12.004

Lallemand est un leader mondial dans le développement, la production et la mise en marché de levures, bactéries et ingrédients dérivés.

© 2026 Rosell Institute for Microbiome and Probiotics by Lallemand. All rights reserved. The information contained herein is business-to-business information and is not intended for the final consumer. It is based on our research and development work and is, to the best of our knowledge, reliable. Lallemand Health Solutions does not assume any liability resulting from the use of its products, as conditions of use are beyond our control. The business-to-business information provided should not be used as a substitute for any form of advice. In all instances, producers and marketers should check local regulatory requirements before use as products may be categorized differently, and consequently different claims may be made depending on the regulations applicable in each country.
 Français
Politique de confidentialité et de cookieAvertissement légalPréférences en matière de cookies

© 2026 Lallemand Inc. Tous droits réservés